All In MedTech

Device Trial Radar · NCT05878483

Autonomous Blood Drawing Optimization and Performance Testing

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44,658

Planned (sponsor's estimate)

Start

Jul 21, 2023

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Vitestro B.V.Not on our public-company list
Sponsor type
Industry
First posted
May 26, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 16 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this pre-market clinical study is to evaluate the performance (efficacy) and safety of an autonomous blood drawing device (Venipuncture Device). The study consists of several phases (A, B1, B2, B3, C1, C2, C3, 0). Phase B1 is a confirmatory, Pivotal Clinical Study, required for regulatory approval, in which non-inferiority should be demonstrated in comparison to manual blood drawing. Phases A, B2, B3, C1, C2, C3 are all exploratory studies, in which the technology and usability is further improved and tested. Phase 0 is an exploratory study for non-invasive technology testing (for example for improvement of ultrasound detection). The study locations are outpatient blood drawing departments, in which patients are included as subjects. Additionally, in Phase A and C1, a small number of volunteers can be included in a non-hospital site (Vitestro Site).

Conditions

  • Venipuncture
  • Phlebotomy

Interventions

  • Venipuncture Device (VD)Device

    The Venipuncture Device is a pre-market medical device that fully automates the blood drawing procedure (also called phlebotomy or venipuncture). It automatically detects a vein using near-infrared and ultrasound imaging technology, robotically inserts a needle, automatically connects blood tubes and applies pressure to the puncture site. During the ADOPT Study, the technology is further improved over time; for example features are released (such as: automated tourniquet). Initially, several manual steps are required to be performed by a device supervisor and operator. At the final stage of the ADOPT Study, Phase C2 and Phase C3, the device has full functionality and only limited manual steps are required to be performed by a device supervisor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First-time venipuncture success rateTime frame: Baseline

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Bispebjerg and Frederiksberg Hospital

    Copenhagen, Denmark · Recruiting

  • Odense University Hospital

    Odense, Denmark · Recruiting

  • OLVG Lab

    Amsterdam, North Holland, Netherlands · Recruiting

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.